You have 0 items in your cart
GLP-1, GIP and glucagon are increasingly discussed together in metabolic research, particularly following the development of compounds designed to interact with more than one receptor pathway.
But what exactly is the difference between them?
Although all three participate in metabolic signalling, GLP-1, GIP and glucagon are distinct peptide hormones that act through different receptors and perform different physiological roles.
Understanding these differences also helps explain the progression from single receptor agonists such as Semaglutide, through dual agonists such as Tirzepatide, to triple agonists such as Retatrutide.
What Are GLP-1, GIP and Glucagon?
GLP-1, GIP and glucagon are naturally occurring peptide hormones involved in the body’s regulation of nutrients and energy.
Their full names are:
GLP-1 — glucagon-like peptide-1
GIP — glucose-dependent insulinotropic polypeptide
Glucagon — a pancreatic peptide hormone involved in maintaining energy and glucose availability
GLP-1 and GIP are generally classified as incretin hormones.
Glucagon is not an incretin hormone.
That distinction is important when comparing their biological roles.
What Is GLP-1?
GLP-1 is a peptide hormone produced primarily by specialised intestinal cells in response to nutrient intake.
It communicates information about nutrient availability to several tissues.
GLP-1 receptors are found in multiple areas of the body, and GLP-1 signalling has been extensively investigated for its involvement in metabolic regulation.
Research has associated GLP-1 receptor activation with processes including:
- glucose-dependent insulin secretion
- regulation of glucagon secretion
- gastrointestinal signalling
- appetite and satiety pathways
- communication between the gastrointestinal system and brain
Because of these functions, the GLP-1 receptor has become one of the most extensively researched targets in modern metabolic science.
What Is the GLP-1 Receptor?
The GLP-1 receptor is a G protein-coupled receptor, commonly abbreviated GPCR.
When GLP-1 or a GLP-1 receptor agonist binds to the receptor, intracellular signalling pathways are activated.
These signals can influence the behaviour of the cell and contribute to wider physiological responses.
Importantly, activating the GLP-1 receptor does not necessarily mean a compound is identical to natural GLP-1.
Researchers can engineer molecules that interact with the same receptor while having different molecular structures and pharmacological properties.
What Is GIP?
GIP is another naturally occurring incretin hormone.
Its full name is glucose-dependent insulinotropic polypeptide.
Historically, GIP was also called gastric inhibitory polypeptide, although glucose-dependent insulinotropic polypeptide more accurately reflects one of its major physiological functions.
Like GLP-1, GIP is released following nutrient intake.
GIP receptor signalling participates in the body’s metabolic response to food and has been investigated in relation to:
- glucose-dependent insulin secretion
- nutrient signalling
- lipid metabolism
- adipose-tissue biology
- wider metabolic regulation
The development of compounds capable of activating both GIP and GLP-1 receptors substantially increased scientific interest in the GIP pathway.
What Is the GIP Receptor?
The GIP receptor is another G protein-coupled receptor.
It responds naturally to GIP but can also be activated by engineered receptor agonists.
Research into GIP signalling has become particularly important because metabolic pathways do not operate independently.
Scientists increasingly study how GIP receptor activity interacts with other signalling systems, especially GLP-1.
This concept helped drive the development of dual receptor agonists.
What Is Glucagon?
Glucagon is a peptide hormone produced primarily by pancreatic alpha cells.
It has traditionally been described as a counter-regulatory hormone to insulin because one of its best-known functions involves helping maintain circulating glucose during periods of fasting.
However, glucagon biology extends beyond this simplified description.
Glucagon signalling is also involved in areas such as:
- hepatic metabolism
- amino-acid metabolism
- lipid metabolism
- nutrient availability
- energy regulation
This broader role has made the glucagon receptor increasingly interesting in multi-receptor metabolic research.
What Is the Glucagon Receptor?
The glucagon receptor is found predominantly in the liver and also belongs to the G protein-coupled receptor family.
Activation of the receptor influences intracellular signalling involved in metabolic regulation.
One important distinction is that glucagon can promote hepatic glucose production.
For this reason, combining glucagon receptor agonism with incretin-related pathways may initially seem counterintuitive.
However, researchers are interested in the overall biological effect produced when several receptor systems are activated in a deliberately balanced way.
That concept is central to modern triple-agonist research.
What Is the Difference Between GLP-1 and GIP?
GLP-1 and GIP are both incretin hormones released in response to nutrients.
Both participate in glucose-dependent insulin signalling.
However, they are different hormones with separate receptors and distinct biological activity.
Their functions overlap in some areas but are not identical.
This is why researchers have investigated whether activating both receptors simultaneously produces different effects from activating GLP-1 alone.
What Is the Difference Between GLP-1 and Glucagon?
Despite the similarity in their names, GLP-1 and glucagon are not the same hormone.
GLP-1 is an incretin hormone involved in nutrient-related metabolic signalling.
Glucagon is primarily produced by pancreatic alpha cells and plays an important role in maintaining energy and glucose availability, particularly during fasting.
They also act through different receptors.
The fact that both can be incorporated into the receptor profile of one engineered compound illustrates how modern metabolic research increasingly combines pathways that were once studied largely independently.
What Is the Difference Between GIP and Glucagon?
GIP is an incretin hormone released following nutrient intake.
Glucagon is a pancreatic hormone strongly associated with fasting physiology and hepatic energy regulation.
They therefore represent different aspects of metabolic signalling.
Investigating both within a multi-receptor molecule allows researchers to study how nutrient-responsive and energy-regulating pathways interact.
Why Are GLP-1 and GIP Called Incretins?
An incretin is a gastrointestinal hormone released in response to nutrient intake that contributes to the insulin response.
GLP-1 and GIP are the two principal incretin hormones studied in humans.
This is why research involving GLP-1 and GIP is frequently described as incretin research.
Glucagon, by contrast, is not classified as an incretin.
Why Are Researchers Combining These Receptors?
Metabolism involves numerous interacting biological signals.
Targeting one receptor can provide information about one pathway.
Targeting multiple receptors allows researchers to investigate how several pathways interact.
This has contributed to an important progression in metabolic research.
Single agonism
A molecule primarily activates one receptor pathway.
Semaglutide is an example of a compound whose principal mechanism involves GLP-1 receptor agonism.
Dual agonism
A molecule activates two receptor pathways.
Tirzepatide is a GIP/GLP-1 dual receptor agonist.
Triple agonism
A molecule activates three receptor pathways.
Retatrutide is being investigated as a GIP/GLP-1/glucagon triple receptor agonist.
The progression from single to dual and triple agonism reflects increasing scientific interest in coordinated metabolic signalling.
Where Does Semaglutide Fit?
Semaglutide primarily acts through the GLP-1 receptor.
It therefore provides a useful example of a GLP-1 receptor agonist when comparing different generations of incretin-related research.
Its mechanism is fundamentally different from compounds deliberately engineered to activate multiple receptor systems.
Where Does Tirzepatide Fit?
Tirzepatide activates both GIP and GLP-1 receptors.
It is therefore commonly described as a dual agonist.
Its development demonstrated the scientific potential of combining two incretin-related receptor pathways within one molecule.
Where Does Retatrutide Fit?
Retatrutide extends the multi-receptor concept further.
It activates:
GIP + GLP-1 + glucagon receptors
This makes Retatrutide a triple receptor agonist.
The glucagon receptor represents the additional pathway distinguishing its receptor profile from Tirzepatide.
Does More Receptors Automatically Mean Better?
No.
The number of receptors targeted does not by itself establish that one compound is superior to another.
Receptor balance, molecular structure, potency, pharmacokinetics, experimental design, clinical evidence and many other factors influence biological outcomes.
A triple agonist should therefore not simply be interpreted as a “stronger” version of a dual or single agonist.
They are different pharmacological approaches that need to be evaluated on their own evidence.
Frequently Asked Questions
Are GLP-1 and GIP the same thing?
No. GLP-1 and GIP are separate incretin hormones that act through different receptors.
Is glucagon a GLP-1?
No. Glucagon and GLP-1 are different peptide hormones with distinct physiological functions and receptors.
Is GIP an incretin?
Yes. GIP and GLP-1 are the two principal incretin hormones.
Is glucagon an incretin?
No. Glucagon is not classified as an incretin hormone.
What receptors does Tirzepatide target?
Tirzepatide activates the GIP and GLP-1 receptors and is therefore described as a dual receptor agonist.
What receptors does Retatrutide target?
Retatrutide activates GIP, GLP-1 and glucagon receptors, making it a triple receptor agonist.
Why does Retatrutide include glucagon activity?
Researchers are investigating whether carefully balanced glucagon receptor signalling can complement GLP-1 and GIP activity through its involvement in energy and nutrient metabolism.
Are GLP-1, GIP and glucagon all peptides?
Yes. All three are peptide hormones involved in metabolic signalling, although their origins and physiological functions differ.
The Key Difference
The simplest way to understand the three pathways is this:
GLP-1 and GIP primarily represent nutrient-responsive incretin signalling, while glucagon contributes another layer of energy and metabolic regulation.
Modern metabolic research increasingly investigates what happens when these pathways are deliberately combined.
That progression helps explain the development of:
GLP-1 agonists → GLP-1/GIP dual agonists → GLP-1/GIP/glucagon triple agonists.
Understanding GLP-1, GIP and glucagon individually therefore provides the foundation for understanding why compounds such as Semaglutide, Tirzepatide and Retatrutide have different receptor profiles.